Focus on their core biz... forget about MVC deal.....if it happens it's bonus... engineering division should enjoy steady growth in their order book going forward.
The developers of the vaccines are currently compiling the data from the first-phase trials and are preparing to start the second phase of their vaccine trials in late December, FDA official Wu Ming-mei (吳明美) told CNA in a phone interview, without specifying the number of vaccines.
The individuals who participated in the clinical trials of the locally developed COVID-19 vaccines did not report any major side effects in the seven days after they were vaccinated, Wu said.
The clinical trials began in late August with at least three vaccines developed by Adimmune Corp., United Biomedical and Medigen Vaccine Biologics Corp., respectively, according to the FDA.
The companies will be eligible to each receive a maximum NT$300 million (US$10.6 million) in additional government funding if they enroll their first participant in the second phase of their clinical trials by Dec. 31, and up to NT$240 million if they miss that deadline but enroll their first participant by Jan. 31, 2021, according to the Central Epidemic Command Center (CECC).
Yesterday while anticipating that 0.10 queue will be cleared...the bulk at 0.095 was suddenly wiped out in seconds... close to 4.:45pm... this either signals a rebound on the cards or quick downward movement today.... but if u intend to buy more and hold ,...0.09 is a "safe" price to enter... any lower will be time to be very greedy... I'll buy a million more shares if lower than 0.08.
M&G's operator is aggressive....Mtronic's operator is happy playing games with bilis... very small time operator that lacks ambition in driving the stock price higher.... wonder if MT's BOD are happy with this low price.
@TraderInvest YOU ARE RIGHT!!! Tomorrow metronic will be RM3, guaranteed! ... unfortunatly, tomorrow bursa is closed, so you can't buy or sell anything. And when bursa opens on Monday, Metronic will be back below 10c...
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
JuliusCeasar
1,216 posts
Posted by JuliusCeasar > 2020-12-23 17:25 | Report Abuse
Hahaha